Drug Trial Radar · NCT07431086
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Actual
Start
Mar 16, 2026
Primary completion
Nov 13, 2026
Study completion Dec 18, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much the study drug is in the blood at different times * How well the study drug works * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
Conditions
- Overweight or Obesity
Interventions
OlatorepatideDrug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 30 weeks
- Severity of TEAEsTime frame: Up to approximately 30 weeks
- Maximum plasma Concentration (Cmax)Time frame: At week 15 and week 24
- Area Under the Concentration time curve from time 0 to 168 hours (AUC0-168h)Time frame: At week 15 and week 24
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Diablo Clinical Research - Flourish Research
Walnut Creek, California
Clinical Site Partners, LLC DBA Flourish Research
Winter Park, Florida
Flourish Research - San Antonio Medical Trials
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.